PT Bukit Asam Tbk (FRA:TBA)

Intra-Cellular Therapies Income Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	43,574,513	42,764,968	38,488,867	42,648,590	29,261,468	17,325,192
Revenue Growth (YoY)	10.95%	11.11%	-9.75%	45.75%	68.89%	-20.48%
Cost of Revenue	36,236,305	34,269,994	28,870,499	24,467,247	15,475,204	12,552,674
Gross Profit	7,338,208	8,494,974	9,618,368	18,181,343	13,786,264	4,772,518
Selling, General & Admin	2,973,046	2,867,205	2,592,997	3,343,456	3,593,731	2,132,233
Other Operating Expenses	436,981	96,839	-240,544	-98,219	233,386	166,633
Operating Expenses	3,410,027	2,964,044	2,352,453	3,245,237	3,827,117	2,298,866
Operating Income	3,928,181	5,530,930	7,265,915	14,936,106	9,959,147	2,473,652
Interest Expense	-191,414	-174,289	-115,964	-140,462	-111,088	-85,742
Interest & Investment Income	250,183	250,183	584,339	428,033	256,856	362,503
Earnings From Equity Investments	668,190	640,335	571,303	829,063	301,220	481,272
Currency Exchange Gain (Loss)	121,488	121,488	-63,206	209,315	-122	-
Other Non Operating Income (Expenses)	-126,328	-109,401	-88,074	-59,741	-47,338	-
EBT Excluding Unusual Items	4,650,300	6,259,246	8,154,313	16,202,314	10,358,675	3,231,685
Pretax Income	4,650,300	6,259,246	8,154,313	16,202,314	10,358,675	3,231,685
Income Tax Expense	725,336	1,119,823	1,861,792	3,422,887	2,321,787	823,758
Earnings From Continuing Operations	3,924,964	5,139,423	6,292,521	12,779,427	8,036,888	2,407,927
Minority Interest in Earnings	-21,038	-35,703	-186,665	-211,845	-127,775	-21,108
Net Income	3,903,926	5,103,720	6,105,856	12,567,582	7,909,113	2,386,819
Net Income to Common	3,903,926	5,103,720	6,105,856	12,567,582	7,909,113	2,386,819
Net Income Growth	-27.21%	-16.41%	-51.42%	58.90%	231.37%	-41.17%
Shares Outstanding (Basic)	-	11,507	11,487	11,487	11,268	11,186
Shares Outstanding (Diluted)	-	11,507	11,487	11,487	11,268	11,186
Shares Change (YoY)	-	0.18%	-	1.95%	0.74%	2.40%
EPS (Basic)	-	443.51	531.54	1094.05	701.91	213.38
EPS (Diluted)	-	443.51	531.54	1094.00	701.91	213.38
EPS Growth	-	-16.56%	-51.41%	55.86%	228.95%	-42.55%
Free Cash Flow	2,404,115	3,817,304	2,167,461	11,638,303	9,846,123	2,798,570
Free Cash Flow Per Share	-	331.72	188.69	1013.15	873.82	250.19
Dividend Per Share	-	-	398.000	1094.000	689.000	75.000
Dividend Growth	-	-	-63.62%	58.78%	818.67%	-76.99%
Gross Margin	16.84%	19.86%	24.99%	42.63%	47.11%	27.55%
Operating Margin	9.01%	12.93%	18.88%	35.02%	34.03%	14.28%
Profit Margin	8.96%	11.93%	15.86%	29.47%	27.03%	13.78%
Free Cash Flow Margin	5.52%	8.93%	5.63%	27.29%	33.65%	16.15%
EBITDA	5,163,626	6,610,692	8,588,575	16,000,730	10,772,971	3,145,571
EBITDA Margin	11.85%	15.46%	22.31%	37.52%	36.82%	18.16%
D&A For EBITDA	1,235,445	1,079,762	1,322,660	1,064,624	813,824	671,919
EBIT	3,928,181	5,530,930	7,265,915	14,936,106	9,959,147	2,473,652
EBIT Margin	9.01%	12.93%	18.88%	35.02%	34.03%	14.28%
Effective Tax Rate	15.60%	17.89%	22.83%	21.13%	22.41%	25.49%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.